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Protein biomarkers offer major benefits for diagnosis and monitoring of disease processes. Recent advances in
protein mass spectrometry make it feasible to use this very sensitive technology to detect and quantify proteins in
blood. To explore the potential of blood biomarkers, we conducted a thorough review to evaluate the reliability of
data in the literature and to determine the spectrum of proteins reported to exist in blood with a goal of creating a
Federated Database of Blood Proteins (FDBP). A unique feature of our approach is the use of a SQL database for all
of the peptide data; the power of the SQL database combined with standard informatic algorithms such as BLAST
and the statistical analysis system (SAS) allowed the rapid annotation and analysis of the database without the need
to create special programs to manage the data. Our mathematical analysis and review shows that in addition to
the usual secreted proteins found in blood, there are many reports of intracellular proteins and good agreement on
transcription factors, DNA remodelling factors in addition to cellular receptors and their signal transduction
enzymes. Overall, we have catalogued about 12,130 proteins identified by at least one unique peptide, and of these
3858 have 3 or more peptide correlations. The FDBP with annotations should facilitate testing blood for specific
disease biomarkers.Introduction
Most human diseases involve the changes in the expres-
sion of normal proteins, or the creation of abnormal
proteins, that disrupt physiology; such protein changes
can arise from mutations, viruses, chemicals, radiation,
free radicals, ischemia, disease or other the sources. In
many instances these proteins may appear in blood thus
providing an easily accessible biomarker that may give
insight into the disease process.
Proteins that are specifically expressed in certain tissue
types or cells may be useful markers of disease. Prostate
specific antigen (PSA) is not selective for malignant
disease but is a tissue-specific kalikrein protease that
indicates benign and cancerous proliferation of prostate
tissue and cells [1]. Transcription factors, DNA binding
and RNA binding zinc finger proteins, chromatin re-
modeling proteins, cellular receptors or agonists, and* Correspondence: 4marshal@ryerson.ca
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reproduction in any medium, provided the orcell signaling proteins including oncogenes that may play
a role in cell and tissue differentiation [2], were first re-
ported from the tryptic peptides of blood fluid after par-
tition chromatography [3,4]. The presence of so many
nuclear and cellular factors was unexpected given previous
views on the nature of plasma proteins [5,6]. Now it ap-
pears that the nucleic acid and protein binding factors that
play a regulatory or signal function in specific cell types
[2] may frequently be detected in blood and have clinical
diagnostic/prognostic or even therapeutic value [7-9].
The proteins and endogenous peptides of human plasma
may be randomly and independently sampled, identified
by liquid chromatography and tandem mass spectrometry,
followed by log transformation and comparative statistical
analysis by ANOVA [10-12]; with the current generation
of mass spectrometers, these processes are relatively sim-
ple and accessible to many laboratories. However, to facili-
tate routine use in biomarker studies, we have created a
federated database of all proteins and peptides reported in
blood. Here we provide for the first time the specific iden-
tity of the set of cellular regulatory proteins detected withl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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human serum/plasma by liquid chromatography and
tandem mass spectrometry that show great promise as
potential biomarkers and therapeutic targets. The good
agreement on peptides from the same cellular proteins by
different research groups, together with the capacity of
mass spectrometry to compare blood samples at the level
of the parent peptide and fragment ion intensity using
ANOVA, indicates that conditions for the detailed analysis
of blood fluids between diseases and physiological states
may now exist [10-12].
Although several organizations and individuals have
published large data sets of proteins in blood, it remains
to provide an SQL database by a systematic compilation
and analysis of publically available data sets. This math-
ematical review of published data evaluates the reliability
of the data in 11 published reports [13-23] and includes
a federated database of all of the proteins and peptides
detected in blood. The new SQL based, federated data-
base of blood proteins (FDBP) available in toto with this
publication will provide a good starting point for groups
wishing to evaluate various peptides in blood as bio-
markers of disease.
Construction and analysis of the federated
database of blood proteins
Federated protein sequence library
A federated database of protein sequences was assembled
by downloading protein sequences from RefSeq, Ensembl,
SwissProt, Trembl or Uniprot that contain sequences from
many sources to yield a non-redundant set of proteins,
protein fragments, splice variants and alleles that contains
over 193,000 possible protein sequences representing dif-
ferent genes, isoforms, transcript lengths, splice variants,
alleles, and recorded nucleic sequences.
Meta database approach
A separate computer program was written to parse each
of the publicly available serum and plasma proteomic
data [13-23]. The data of Zhu et al [20] is a reanalysis of
the raw data of Marshall et al [3]. The data of Bowden et
al is the analysis of the raw data of the HuPO PPP con-
sortium downloaded from TRANCHE website and cal-
culated by X!TANDEM [23]. The results were reported
in different formats with accession numbers and FASTA
protein sequences obtained from RefSeq, Swiss, protein,
ENSEMBL, Uniprot IPI or other predicted protein se-
quences. To facilitate the easy analysis, the peptides and
proteins from the independently published reports of
human serum/plasma proteins were then transferred to
a single SQL database. It has been previously suggested
that it is challenging to derive high confidence identifica-
tions of human serum/plasma proteins [4] and that most
proteomic identifications are false positive results usingthe “empirical model” based on putatively pure protein
standards verses a decoy library [24]. However, statistical
confidence in protein identification certainly increases
through replication and independent identification of
the same proteins [25,26]. Moreover the so called FDR
used in proteomics, based on the empirical model, has
been shown to disagree with classical statistical analyses
by many orders of magnitude and to incorrectly reject
well known blood proteins, including albumin, resulting
is a large type II error (false negative) of protein identifi-
cation [10,27]. Comparing the goodness-of-fit scores of
authentic MS/MS spectra versus random or noise spec-
tra [27,28] shows that the score distributions of real
spectra correlations can be easily separated from false
positive results [27,28] so long as the data are collected
with a high signal to noise ratio [10-12].
Confidence is known to increase with the number of
peptides identified from each protein [25,26] and so the
peptide to protein distribution of a data set is a simple
means to infer the statistical reliability of the data
[10-12]. Previously, control experiments using random
libraries and random or noise spectra showed that
roughly 88% of false positive proteins were identified by
1 peptide, about 11% of false positive hits show 2 pep-
tides, and about 1% of false positive hits show 3 or more
peptides: Experiments with random libraries of amino
acid sequences, decoy libraries and random spectra all
agree that proteins observed with at least 3 peptides
show a false positive rate of less than 1% [27,28] and a
low false positive rate (type I error) [25,27]. LC-ESI-MS/
MS data sets that have been recorded with a high signal
to noise ratio in replicated experiments show up to tens
or hundreds of peptide detections per protein and thus a
low probability of false positive results. In contrast, the
peptide to protein distribution of noise spectra was not
different from random spectra [27,28]. An emphasis on
replication, and good agreement between independent
experiments, is a pragmatic method to provide confi-
dence in sensitive ion trap data.
Analysis of the data sets
The database of HuPO plasma proteome results [23] and
all previously published blood results [29] were obtained
as previously described [20]. The HuPO consortium raw
data was obtained from the TRANCHE website and ana-
lyzed with X!TANDEM [29,30]. The resulting proteins
were detected from independent experiments using differ-
ent instruments and/or correlation algorithms including
X!TANDEM [19], MASCOT, OMSSA or others [18] and
SEQUEST [31,32]. The advantages and disadvantages of
these approaches have previously been considered and the
statistical reliability of the data set has previously been es-
timated [29]. The protein and peptide sequences reported,
or where required the accession numbers, were used to
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protein library to create the FDBP.
The federated sum of the peptide and protein se-
quences reported, and the number of observations, were
calculated using Structured Query Language (SQL). The
SQL server database system was installed on a personal
computer (PC) using the Windows server operating sys-
tem to create the FDBP: The redundant and distinct
protein sequences were determined using SQL [29]. The
resulting FDBP was subsequently analyzed on a 64 bit
PC with SQL Access as previously described [23].
The BLAST (Basic Local Alignment of Sequence Tool)
algorithm [33] provides a standardized way to search for
homologous regions on proteins and quantify the level
of similarity within a set of proteins; BLAST was down-
loaded from NCBI and installed on a PC [33]. A subset
of blood protein results were organized into a BLAST
matrix for the purpose of comparing BLAST to the
automatic features of SQL. The results of the BLAST
analysis for each sequence were also captured in the
SQL database alongside the corresponding proteins. The
top scoring BLASTp alignment for every query protein
was considered a “match” if the identity was greater than
75% of the full length and if the alignment contained a
perfect match string of at least 20 amino acids [29].
The SQL database of the peptides and proteins mapped
to the federated protein library was explored using SAS to
generate the graphs provided [23]. The data were graphed
in SAS JMP after sorting the parameter(s) of interest in
descending order using the Tables - Sort menu. The
resulting data was plotted versus increasing protein
number using the graphic features inherent to the SAS.
The peptide to protein distributions of the blood data
compared to that of randomized libraries [25] or ran-
domized spectra or noise indicate that the proteins de-
tected by three or more different peptides show a low
expectation of false positive results ≤ 1% FDR
[10,23,27-29]. The graphs were exported from SAS as
rich text format files. The data were analyzed on a 64 bit
PC with SAS JMP as previously described [23]. After
comparing BLAST versus SQL we imported the pep-
tides, proteins, and ion characteristics including inten-
sity values from Liu et al 2007 and included these in the
SQL database only for summary of the FBPD.
The peptide and protein sequences were used as quer-
ies to obtain the protein descriptions from RefSeq,
Ensembl, Swiss Prot and other protein libraries that were
concatenated with semicolons. Similarly BLAST was
used to obtain the molecular identity or molecular func-
tions, biological processes and sub cellular localization
of the proteins found in human blood where gene ontol-
ogy terms (GO) and gene symbols were available. The
peptide and protein sequences along with the accession
numbers, GO terms and the results of bio-informaticcalculations from the GO and BLAST analysis are orga-
nized and stored together.
The cellular factors of specific interest from the FDBP
are made available in the Additional files. The cellular
proteins of blood fluids listed in the FDBP are presented
in a graphical form using the Search Tool for the
Retrieval of Interacting Genes/Proteins (STRING) [34]
that automatically generated a list of gene symbols from
the protein descriptions provided in the FDBP. How-
ever, more complete information can be found in the
Additional files.
Results
Comparison of SQL versus BLAST analysis
We compared the BLAST analysis of amino acid se-
quences versus SQL analysis at the level of peptides and
proteins on a large subset of the data to compare the
methods and characterize the distributions of blood pro-
tein data. BLAST analysis [33] of a set of 44,019 reported
proteins at a standard of 75% full length and 20 contigu-
ous amino acids, compressed these to a set of 17,506
protein types. Among the proteins, 14,224 had no close
homologues in the reference library of protein se-
quences; the remaining proteins occurred at least twice
in the FDBP. After compression by BLAST a set of 7,707
proteins types were detected by at least three peptides.
Based on the BLAST analysis the available annotation
such as descriptions, GO data and accession numbers
could be connected with the appropriate database entry.
Homology expectation value
The chance that the homology observed between pro-
teins was just a random coincidence is the expectation
value (e). The expectation value of the homology ob-
served between the reported serum/plasma proteins was
determined by the BLAST algorithm. Some 13,010 pro-
teins were found to have significant homology in the
FDBP by BLAST. The distribution of BLASTp signifi-
cance values were captured in the SQL database and
plotted in SAS (Figure 1). Note that ~ eight thousand
protein matches showed probability values less than
E-180 (machine 0) and so are not shown. BLAST reduc-
tion compressed the 13,010 proteins into about 3262
protein types (Figure 1).
Sequence gap analysis
Proteins that have homology may show strings of se-
quence with perfect alignment, interspersed by breaks or
openings where the sequences are not similar or miss-
ing. The distribution of gap openings in homologous
proteins was calculated by BLAST (Figure 2). Note that
almost 9000 protein matches showed perfect alignments
with no gaps in the matched amino acid sequence. In



















Figure 1 The probability of homology between a subset of
27,254 distinct blood proteins as determined by the BLAST
algorithm. Note that about eight thousands proteins matches


















Figure 3 The distribution of Log10 protein match alignment
lengths. Note that almost 13,000 protein matches showed protein
alignments of greater than 100 contiguous amino acids. Typically a
contiguous stretch of 20 amino acids is considered sufficient evidence
to indicate a potential structural relationship between proteins.
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In a small number of proteins more than 30 gaps were
observed along the length of the homologous proteins
(Figure 2).
Protein alignment length
The distribution of Log10 protein match alignment lengths
was calculated by BLAST (Figure 3). Almost 13,000 pro-
tein matches showed protein alignments of greater than
100 contiguous amino acids. Typically, a contiguous
stretch of 20 amino acids is considered sufficient evidence
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Figure 2 The distribution of gap openings in homologous
proteins as calculated by BLAST. Note that almost 9000 protein
matches showed perfect alignments with no gaps in the matched
amino acid sequences. In contrast, a small subset of about one
thousand proteins showed three or more gaps in the
matched sequence.Protein mis-matches
Sometimes there are strings of sequence that in general
show homology but have short regions where the se-
quence is not identical. The plot of log mismatches to
proteins was calculated by BLAST (Figure 4). More than
four thousand proteins had zero mismatches along the
protein length. In contrast, about two thousand proteins
showed at least ten, to as high as one thousand mis-














Figure 4 The plot of log10 mis matches to protein match
number. Note that more than seven thousand proteins had few
or no mis matches along the protein length. In contrast about
four thousand proteins showed between 10 and one thousand
mis-matches along the matched protein length.
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The plot of percentage identity between protein matches
was calculated by BLAST (Figure 5). Note that some twelve
thousand protein matches show at least 75% identity over
the full length of the query sequence that typically indicates
a clear structural relationship between the protein sequences.
SQL analysis
SQL analysis is based on the peptide or protein sequences.
Liquid chromatography, coupled to electrospray ionization
with tandem mass spectrometry can identify thousands of
protein types, but there may be ambiguity in the results
when there is a low level of peptide coverage and the pep-
tides are shared by more than one protein. A total of
75,432 peptides produced a list of 57,784 peptides after
the removal of duplicates using the distinct function of
SQL. However, some of these peptides represented smaller
pieces of other peptides and removal of these subsets of
peptides gave 50,452 unique peptide sequences.
Redundant proteins by SQL
Analysis of these raw data returned a total of 44,019
proteins of which 10,056 had three peptides or more;
however, many proteins had identical sequences, but dif-
ferent protein names or accession numbers. The redun-
dant peptide to protein count for the raw data showed
just over half the proteins from each group separately
had only one peptide reported but that a set of about
ten thousand had three or more peptides including some
proteins with up to 500 redundant identification
(Figure 6). Hence the redundant peptide to protein dis-



















Figure 5 The plot of percentage identity between protein
matches. Note that some twelve thousand protein matches show
at least 70% identity over the full length of the query sequence that
typically indicates a strong structural relationship between the
protein sequences.that of random expectation that should show a large
proportion of protein with single peptides and almost no
proteins with high numbers peptides.
Distinct proteins by SQL
Removal of the duplicate proteins gave 27,254 distinct pro-
teins that differed by at least 1 amino acid. After removing
the proteins that were perfect subsets of other sequences,
a total 10,138 unique protein sequences were identified by
3 or more distinct peptide sequences (Figure 7). Based on
the distinct peptide distribution, we concluded that SQL
showed similar trends, but that BLAST reduction may col-
lapse some proteins together that are truly distinct but
have some similar sequence.
Unique or characteristic peptide sequence summary by
SQL
There are many methods that can be used to estimate
the vital statistics of the blood proteome, and perhaps
the most conservative method would be to consider only
proteins identified by at least one peptide that is unique
to that protein and not characteristic of any other protein.
An analysis of all the data reveals a set of 91,373 peptides
from published studies on human serum/plasma of which
12,130 proteins that were detected by at least one unique
peptide not shared with other proteins and of these 3858
had a total of at least three peptide identifications, confer-
ring near certain molecular identity.
The types of proteins detected in blood/serum
Broad spectrum of proteins detected in blood/serum
A major goal of this review was to determine the
spectrum of proteins present in plasma/serum. A large





















Figure 6 The log10 peptide to protein distribution of the
human blood proteins. A set of published human blood data were
parsed into SQL and the distributions of the data derived and
















Figure 7 The plot of distinct peptide count versus distinct
protein number. Note that about 12,000 proteins were only
detected by 1 peptide. In contrast, a total of 10,138 distinct
protein sequences were correlated by 3 or more different peptide
sequences.
Table 1 The distribution of cell location in the blood
protein SQLdatabase
Cellular location Count Frequency
Total 22926 1
Nucleus, 2958 0.12902
Membrane, integral to membrane, 1330 0.05801
Cytoplasm, 810 0.03533
Extracellular region, 624 0.02722
Integral to membrane, 531 0.02316
Intracellular, 447 0.0195
Nucleus, cytoplasm, 414 0.01806
Intracellular, nucleus, 403 0.01758
Extracellular space, 363 0.01583
Membrane, 298 0.013
Mitochondrion, 269 0.01173
Plasma membrane, integral to membrane, 265 0.01156
Extracellular region, extracellular space, 264 0.01152
Cellular_component, 203 0.00885
Ubiquitin ligase complex, 200 0.00872
Ubiquitin ligase complex, 191 0.00833
Extracellular region, proteinaceous extracellular
matrix,
179 0.00799
Nucleus, cytoplasm, 142 0.00619
Nucleus, nucleus, 131 0.00571
Plasma membrane, integral to plasma membrane, 129 0.00563
Integral to plasma membrane, membrane, 125 0.00545
Plasma membrane, integral to plasma membrane, 103 0.00449
Cytoskeleton, 95 0.00414
Proteinaceous extracellular matrix, 93 0.00406
Endoplasmic reticulum, endoplasmic reticulum
membrane, membrane, integral membrane,
80 0.00349
Nucleosome, nucleus, chromosome, 78 0.0034
Intracellular, ribosome, 74 0.00323
Plasma membrane, 73 0.00318
Intracellular, cytoplasm, 72 0.00314
Lysosome, 72 0.00314
Intracellular, nucleus, cytoplasm, 71 0.0031
Actin cytoskeleton, 70 0.00305
Endoplasmic reticulum, 69 0.00301
Cytoplasm, cytoskeleton, 68 0.00297
Plasma membrane, integral to membrane, 66 0.00288
Cytosol, 65 0.00284
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processes. In addition to the usual proteins expected in
the blood e.g., albumin, haemoglobin, gamma globulin,
fibrinogen, ferritin, etc, many intracellular proteins from
different tissues were found in the FDBPs. We trans-
ferred the annotations found in various databases to our
FDBP and then used the SQL database to analyze the
various classes of proteins. All cellular locations were
observed in the dataset including the nucleus, integral
membrane, cytosol and extracellular matrix (Table 1).
The most common molecular functions were protein
binding, DNA binding, “unknown”, DNA binding, Ca++
binding, Zn++ ion binding and receptor activity (Table 2).
The most common biological processes observed were
DNA-dependent transcription regulation, proteolysis,
transport, signal transduction and metabolic processes
(Table 3). The following sections give a summary the
major classes of proteins found in blood.
DNA binding factors and transcription factors
The database includes many DNA binding factors,
DNA remodeling enzymes, RNA binding proteins, and
receptor-associated signal pathway proteins. Zinc finger
and other nucleic acid binding domains, including do-
mains known to bind RNA have been detected in
serum/plasma by a variety of methods [3,19] and predate
the recent discovery of RNA and nucleic acids in blood
[35]. The prevalence of proteins linked to transcriptional
regulation, DNA remodeling, RNA binding and signal
transduction was in agreement between groups and con-
firmed the unexpected presence of these circulating
Table 1 The distribution of cell location in the blood
protein SQLdatabase (Continued)
Intracellular, nucleus, 64 0.00279
Membrane fraction, integral to plasma membrane, 64 0.00279
Ubiquitin ligase complex, nucleus, 63 0.00275
Membrane fraction, integral to plasma membrane,
membrane,
60 0.00262
For more complete information see Additional files.
Table 2 The distribution of molecular functions in the
blood protein SQL database
Molecular function Count Frequency
Total 24031 1
Protein binding, 1373 0.05713
DNA binding, 348 0.01448
Binding, 340 0.01415
Calcium ion binding, 226 0.0094
Transcription factor activity, 225 0.00936
Structural molecule activity, 196 0.00816
Receptor activity, 193 0.00803
Calcium ion binding, protein binding, 185 0.0077
DNA binding, zinc ion binding, 179 0.00745
DNA binding, zinc ion binding, metal ion binding, 159 0.00662
Structural constituent of ribosome, 149 0.0062
Nucleic acid binding, zinc ion binding, 134 0.00558
Protein binding, zinc ion binding, metal ion
binding,
125 0.0052
Catalytic activity, 109 0.00454
Nucleic acid binding, 106 0.00441
Calcium ion binding, protein binding, 104 0.00433
GTPase activator activity, 104 0.00433
Extracellular matrix structural constituent, 101 0.0042
RNA binding, 89 0.0037
Ubiquitin-protein ligase activity, zinc ion binding, 89 0.0037
Serine-type endopeptidase inhibitor activity, 88 0.00366
Receptor activity, olfactory receptor activity, 85 .00354
Transcription factor activity, zinc ion binding, 81 0.00337
Transporter activity, 79 0.00329
Actin binding, 76 0.00316
Signal transducer activity, 76 0.00316
Nucleotide binding, protein serine/threonine
kinase
75 0.00312
Nucleotide binding, ATP binding, 68 0.00283
Nucleotide binding, RNA binding, 66 0.00275
Transcription factor, sequence-specific DNA
binding
63 0.00262
Receptor binding, 62 0.00258
Hydrolase activity, 60 0.0025
Nucleotide binding, RNA binding, protein binding, 59 0.00246
Protein binding, zinc ion binding, 55 0.00229
Structural constituent of cytoskeleton, 51 0.00212
Nucleic acid binding, zinc ion binding, metal ion
binding,
50 0.00208
Molecular_function, protein binding, 48 0.002
RNA binding, protein binding, 48 0.002
Sugar binding, 48 0.002
Transcription factor activity, RNA polymerase II 46 0.00191
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to confer tissue and cell specificity were identified [36].
For example, the sine oculis homeobox homolog 3 (SIX3)
was observed with many potential functional partners or
related proteins. Members of the proto-oncogenes, or
HLH transcription factor super family members, including
myb, myc max and their associated binding factors, the
AP-1 dimmers eg. isoforms of FOS, JUN, the serum re-
sponse factor (SRF) and functionally associated proteins,
such as ELK or ETS factors were detected . The transcrip-
tion proteins in blood show a network relationship cen-
tered around FOS, JUN, ETS, MYB, MAX and HOX
factors. In addition, many other transcription factors and
proto-oncogenes containing DNA binding transcription
factors, such as retinoblastoma-like 2 (RBL2) or V-Rel
member of the Rel/NFKB family, were identified in
serum/plasma with at least one peptide by mass spec-
trometry (Figure 8, Additional file 1).
Chromatin remodelling and nucleic acid modification
enzymes
Proteins containing chromo and bromo domains, chroma-
tin remodelling enzymes, histone modifications enzymes,
as well as histones and high mobility proteins were
clearly detected. The DNA remodeling proteins, includ-
ing SMARC, bromo and chromo domains, SWI/SNF pro-
tein, including SMARC, bromo and chromo domains,
SWI/SNF protein, histone modification enzymes, medi-
ator proteins that are required for gene expression have
been clearly detected with agreement by multiple peptides
in serum/plasma. In addition, many other similar pro-
teins exist in the FDBP of serum/plasma proteins: Actin
and microtubule cytoskeleton proteins; myeloid/lymphoid
or mixed-lineage leukemia (MLL) protein 3 homolog;
chromosome assembly factors and the chromosome
modifying proteins (CHMP); the E1A binding protein
(EP); bromodomain and WD repeat-containing protein 1,
required for the regulation of the cytoskeleton and cell
shape [37]; mediator proteins (MED) that forge the phys-
ical connection between the DNA dependent transcrip-
tion factors and the RNA polymerase; proteins with
structural or functional similarity to transcription elong-
ation factors (Figure 9, Additional file 2).
Table 2 The distribution of molecular functions in the
blood protein SQL database (Continued)
DNA binding, protein binding, zinc ion binding, 45 0.00187
Actin binding, actin binding, actin binding,
structural
44 0.00183
Growth factor activity, 44 0.00183
For more complete information see Additional files.
Table 3 The distribution of biological processes in the
blood protein SQL database
Biological process Count Frequency
Total 22069 1
Transcription, regulation of transcription,
DNA-dependent,
811 0.03674




Signal transduction, 209 0.00947
Cell adhesion, 173 0.00784
Metabolic process, 164 0.00743
Protein amino acid phosphorylation, 153 0.00693
Protein ubiquitination, 139 0.0063
Ubiquitin cycle, 134 0.00607
Electron transport, 122 0.00553
Intracellular signaling cascade, 114 0.00517
Protein amino acid dephosphorylation, 105 0.00476
Multicellular organismal development, 101 0.00458
Phosphate transport, 98 0.00444
Protein folding, 90 0.00408
Cell adhesion, homophilic cell adhesion, 86 0.0039
Immune response, 85 0.00385




Protein transport, 81 0.00367
mRNA processing, RNA splicing, 75 0.0034
Nucleosome assembly, 72 0.00326
Epidermis development, 61 0.00276
Cell adhesion, homophilic cell adhesion, 58 0.00263
Small GTPase mediated signal transduction, 57 0.00258
Cation transport, calcium ion transport, 56 0.00254
Cell surface receptor linked signal transduction, 56 0.00254
Cytoskeletal anchoring, 55 0.00249
Signal transduction, G-protein coupled receptor
protein factor
55 0.00249
Signal transduction, G-protein coupled receptor
protein
47 0.00213
Protein modification, 46 0.00208
Ion transport, 45 0.00204
Nucleosome assembly, chromosome organization 45 0.00204
Muscle contraction, cytoskeletal anchoring,
development
44 0.00199
rRNA processing, 44 0.00199
Spermatogenesis, 44 0.00199
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A large number of zinc finger proteins that have been
shown to bind nucleic acid sequences were observed in
serum/plasma. RNA/DNA binding regulatory factors that
contain many different combinations of domains, includ-
ing zinc, ring, PhD, SET, Scan, and many others, were
abundant in the serum/plasma. As one of many examples,
RNA-binding protein 39 (RBM39), also called hepatocel-
lular carcinoma protein 1, is a transcriptional co-activator
for steroid nuclear receptors ESR1/ER-alpha, ESR2/ER-
beta, plus JUN/AP-1 and may be involved in splicing pre-
mRNA [38] (Figure 10, Additional file 3).
SNAPS, SNARES, kinesin, secretion apparatus and exosome
components
Many proteins that are functionally associated with the se-
cretion pathway from cells or the formation of exosomes
were detected in the serum or plasma. SNAP and SNARE
proteins, such as GOSR1, that regulate synaptic mem-
brane exocytosis via the membrane fusion of targeted
vesicles were detected, such as GOSR1. Serum/plasma
also contains many other similar proteins: The calcium
dependent secretion activator CADPS and the regulator
synaptic membrane exocytosis protein(s) RIMS4 were also
detected. Endosome antigens, such as EEA1 were ob-
served. Proteins associated with Golgi apparatus that gov-
erns secretion were also detected. Furthermore, and
exosome components 8, 10 and RRP46, among others,
have been observed (Figure 11, Additional file 4).
Cellular receptors and signal transduction factors
An extraordinary wealth of ligands, receptors, receptor-
associated-kinases, phosphatases, adaptor proteins,
nucleotide-binding G proteins, exchange factors, activating
factors and many other binding proteins along the signal
transduction pathways of cells have now been clearly ob-
served in plasma. For example the protein kalirin (KALRN)
that apparently is a RHOGEF kinase isoform was clearly
detected. Well-known receptors, such as the adrenergic
(ADRA) or GABA receptor (GABBR), plus unknown or
unusual receptor factors were detected. For example, the
BTB/POZ domain-containing protein KCTD12, which
may be a subunit of the GABA-B receptor, was observed.
Thyroid receptor-interacting protein 11, encoded by the
TRIP11 gene, functionally interacts with thyroid hormone
receptors alpha and beta, and the Retinoblastoma (RBB)
Table 3 The distribution of biological processes in the
blood protein SQL database (Continued)
Carbohydrate metabolic process, 43 0.00195
Muscle development, 43 0.00195
Acute-phase response, 41 0.00186
Glycolysis, 41 0.00186
Intracellular protein transport, 41 0.00186
For further information see Additional files.
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surface recognition events such as immune response, cell
growth, differentiation, metabolism and survival, including
Fc, MHC, scavenger or Cadherin and EGF LAG seven-
pass G Protein Coupled Receptors (GPCRs) -type 3,
Integrin beta-8 (ITGB8) were detected. The receptor-type
tyrosine-protein phosphatase beta that is a negative regula-
tor of growth factor and cadherin receptors was alsoFigure 8 The contents of the database queried for transcription-assoc
may be found in Additional file 1. The figure was produced using STRING e
blue concurrence; black co-expression; purple experiments; cyan databasesidentified. There were members of both trimeric and
monomeric G-protein pathways, such as small G protein
signalling modulator 3, or the metabotropic glutamate re-
ceptor 3 which signals via a timeric GTPase (G protein)
that inhibits adenylate cyclase activity. Rho guanine nu-
cleotide exchange factor 17 (ARHGEF17) is a protein that
swaps GDP for GTP to enable the function of monomeric
GTPase (G protein). In contrast, Rho GTPase-activating
protein 29 (ARHGAP29) is a protein that causes the cataly-
sis of GTP to GDP, turning the G- protein switch off. Rya-
nodine receptor 2 (RYR2) is found in cardiac muscle as
part of a calcium channel and mutations in RYR2 gene
may be associated with Alzheimer’s, tachycardia, arrhyth-
mogenic right ventricular dysplasia [40]. Inositol 1,4,5-tris-
phosphate receptor type (IPTR3) was observed at least 25
times and may play a role in a variety of signalling net-
works. Insulin receptor substrate 4 may act as a second
messenger that participates in the flow of information via aiated proteins are shown without filtering. The full list of factors
vidence view. Colors: Green gene neighborhood; red gene fusion;
; yellow text mining; and grey homology.
Figure 9 DNA remodeling factors in human blood. The contents of the database were queried for DNA remodeling-associated proteins and
are shown without filtering. The full list of factors may be found in Additional file 2. The figure was produced using STRING evidence view. Colors:
Green gene neighborhood; red gene fusion; blue concurrence; black co-expression; purple experiments; cyan databases; yellow text mining; and
grey homology.
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http://www.clinicalproteomicsjournal.com/content/11/1/3chain of phosphorylation events. BRCA1-associated RING
domain protein 1 is a probable E3 ubiquitin-protein ligase
that mediates the formation of ‘Lys-6’-linked polyubiquitin
chains in DNA damage repair, ubiquitination and tran-
scriptional regulation. In addition, a probable ubiquitin
carboxyl-terminal hydrolase was also observed. A greatnumber of well-known cellular signalling proteins, includ-
ing kinases and phosphatases were detected by multiple
groups in agreement. It is striking to consider the many
types of proteins that are now known to mediate signalling
within cells and were apparently found in the plasma at
detectable concentrations (Figure 12, Additional file 5).
Figure 10 RNA binding and zinc finger proteins. The contents of the database were queried for RNA binding or zinc finger-associated
proteins and are shown with filtering at n = 3. The full list of factors may be found in Additional file 3. The figure was produced using STRING
evidence view. Colors: Green gene neighborhood; red gene fusion; blue concurrence; black co-expression; purple experiments; cyan databases;
yellow text mining; and grey homology.
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http://www.clinicalproteomicsjournal.com/content/11/1/3Cytokines, chemokines, interleukins and tumor necrosis
factor receptors and binding proteins
The chemokines, cytokines, interleukins, and tumor ne-
crosis factor ligands were apparently below the detectionlimit of the sample preparation and electropsray LC-MS
systems employed [10,41-44]. However, the receptors
and associated proteins of chemokines, cytokines, tumor
necrosis factors and interleukins were observed. For
Figure 11 The contents of the database were queried for
secretion-associated proteins and are shown without filtering.
The full list of protein may be found in Additional file 4. The
figure was produced using STRING evidence view. Colors: Green
gene neighborhood; red gene fusion; blue concurrence; black
co-expression; purple experiments; cyan databases; yellow text
mining; and grey homology.
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was clearly detected. Interleukin 1 receptor-like 2
(IR1RL2) was well detected from plasma. Receptors for
proteins with homology to TNFalpha and other cyto-
kines that function in tissue differentiation were identi-
fied in serum/plasma, such as the receptor tyrosine
kinase (RET) that binds the Glial cell line-derived neuro-
trophic factor. A wide range of proteins annotated as
part of cytokines, chemokines and interleukins pathways
were observed (Figure 13, Additional file 6). While cyto-
kine and chemokine receptors and binding proteins were
detected, the ligand factors were below detectable levels,
as expected.
Growth factor receptors and binding proteins
Epidermal growth factor receptor (EGFR) and its sub-
strates were observed in plasma with multiple peptides.
Ligands that are present in higher concentrations than cy-
tokines, such as Insulin like growth factor [41] were well
observed by multiple groups. Insulin-like growth factor-
binding receptor that contains an IGFBP N-terminal
and a Thyroglobulin type-1 domain was detected in the
plasma; the ligand insulin like growth factor has previ-
ously been identified in blood [41]. Proteins with hom-
ology to growth factors, such as the multiple epidermal
growth factor-like domains 8, which is an EGF domain
protein involved in signalling, were detected. Receptor
tyrosine-kinase Erb interacting and binding proteins were
observed. In addition, fibroblast growth factor, opioid,
and FMS like tyrosine kinase growth factor receptors orbinding proteins were observed (Figure 14, Additional
file 7). However, while growth factor receptors and bind-
ing proteins were detected, the growth factors themselves,




A number of strategies have been suggested for the ana-
lysis of proteomic data that require proteomic-specific
data storage and analysis platforms. The data analysis
strategies generally advocate the storage of raw data in
xml or text files with proteomics-specific software rou-
tines to manage, analyze and summarize the data
[45-47]. In contrast, we proposed that the generic data
analysis systems such as SQL, BLAST, and a generic
statistical analysis system (SAS) may be used to organize
and analyze proteomic data, using this broadly available
and well tested software [10,12,20,23,29,48]. When con-
sidering the choice of a data analysis system, it is im-
portant to note the differences in proteomic versus
genomic data. Genomic data is the linear character se-
quence of about 3 billion base pairs. The proteome cor-
responds to only about 1% of the genome, comprising
22,000 protein types to date. In addition, there is a 3 to
1 compression of the data from bases to amino acids
and so the protein sequence data is no more than 0.3%
that of the genome. In many instances, only a few repre-
sentative peptides have been recorded from each protein,
and so the sequence data collapses to less than 0.1% of
the genome sequence. However, individual peptides may
be detected repetitively and these detections can be stored
as numeric information. Hence proteomics data sets will
contain at least a thousand fold less sequence information
than genomic databases but have much more numerical
data including m/z values and continuous intensity values
from the parent and fragment ions [10,11]. The large
amount of continuous fragment m/z and intensity data
must be connected to the relatively small amount of protein
and peptide sequences or masses [M+H], that are ordinal
or nominal variables, in order to compute the differences in
intensity values over treatments [10,12,20,23,29,48]. The
ion intensity data must be linked to the protein, peptide,
and m/z information in a format that will permit immediate
statistical analysis by generic routines [10-12].
Analytical error in protein identification
When a highly purified protein is analyzed by LC-MS/MS
it is sometimes possible to achieve complete sequence
coverage and therefore unambiguous identification between
highly related sequences. However, when many proteins are
identified and quantified simultaneously, the peptide cover-
age of each protein is not complete and so there may be
more than one protein sequence that matches the detected
Figure 12 The receptor and signal transduction proteins in human blood serum or plasma. The contents of the database wee queried for
receptors, kinases, phosphatase and cell signalling-associated proteins and are shown with filtering at n = 5. The full list of factors may be found
in Additional file 5. The figure was produced using STRING evidence view. Colors: Green gene neighborhood; red gene fusion; blue concurrence;
black co-expression; purple experiments; cyan databases; yellow text mining; and grey homology.
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http://www.clinicalproteomicsjournal.com/content/11/1/3peptides. In some cases, where only a few peptides are de-
tected there may be no way to rule out related proteins
without subsequent investigation. Most proteomic scien-
tists support the concept of creating large databases of pro-
teins from different sources, but there are no universally
accepted processes for creating such databases. We have
chosen to collect data on serum/plasma proteins from sev-
eral published sources to create a FDBP that depends on
the veracity of the methods used to collect, combine and
analyze the data to avoid the pitfalls that might spuriouslyincorporate inappropriate molecules into the FDBP. The
proteins of human blood have been separated by various
methods, including a variety of chromatographic strategies
for separation prior to ionization and the MS/MS spectra
were collected with commercially available quadrupole or
ion trap instruments [23,29]. Together these methods yield
a large number of peptides correlated to a small number of
proteins in sharp contrast to random expectation. It’s has
been suggested that three peptides many be a reasonable
standard to limit false positive rates into protein databases
Figure 13 The cytokine, chemokine and interleukin proteins of human blood plasma or serum. The contents of the database were
queried for cytokines, chemokines, interleukins and tumor necrosis factor associated proteins and are shown without filtering. The full list of
factors may be found in Additional file 6. The figure was produced using STRING evidence view. Colors: Green gene neighborhood; red gene
fusion; blue concurrence; black co-expression; purple experiments; cyan databases; yellow text mining; and grey homology.
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http://www.clinicalproteomicsjournal.com/content/11/1/3based on random protein libraries and calculations based
on random spectra or noise spectra also indicate that the
false positive rate (type I error) estimated from peptide-to-
protein distributions was in agreement with independent
goodness of fit tests of the protein spectra and graphical ap-
proaches [25,27,28].
BLAST versus SQL
Less than half of the human blood proteins have closely
related homologs in the FDBP and there may be partial
sequences, splice variants, or allelic forms of proteins in
the FDBP that differ by at least one amino acid. In some
instances, it may be desirable to collapse proteomic data
to a set of unique or representative protein sequences.
It has been previously shown that the protein databases
can be collapsed into a smaller number of protein typesby listing all perfect subsets under the longest repre-
sentative sequence, or collapsing the proteins using
BLAST analysis with similar results [10-12,20,23,29].
The BLAST criteria of 75% full length homology and 20
contiguous amino acids [20,23,29] is a standard method
to assign structural identity to different proteins. The
standard BLAST algorithm can be used to quantify the
extent of identity between proteins and domains and to
annotate them. We conclude the BLAST algorithm is a
sufficient metric to distinguish protein types that flexibly
discovers relationships between proteins which can then
be directly captured in an SQL database. The strategy of
parsing control or test data sets, using existing software,
such as SQL, for assembly prior to BLAST or statistical
analysis by generic routines like SAS or R, may be
appropriate for annotation and quantitative analysis
Figure 14 The growth factor proteins of human blood plasma or serum. The contents of the database were queried for growth factor
associated proteins and are shown without filtering. The full list of factors may be found in Additional file 7. The figure was produced using
STRING evidence view. Colors: Green gene neighborhood; red gene fusion; blue concurrence; black co-expression; purple experiments; cyan
databases; yellow text mining; and grey homology.
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http://www.clinicalproteomicsjournal.com/content/11/1/3of proteomic data. Moreover, as shown here, the results
of BLAST can be conveniently stored in the same
SQL source database, dramatically simplifying the
organization and increasing archival quality of the data
with convenient analysis and graphical presentation
the generic statistical analysis software such as SAS.
We conclude that up to 17,506 protein types might exist
in blood based on homology to proteins where pep-
tides were obtained and of these about 7,707 of these
are identified with reasonable certainty. The redundant
protein count is the number of times any MS/MS
spectrum has been correlated to a peptide from any pro-
tein sequence(s). The same peptide, and therefore pro-
tein(s), may be detected in replicate experiments and
the redundant peptide count provided yields an estimate
of the relative levels of detection. Some peptides are
found in protein sequences that are identical between
protein libraries, and the many equivalent library acces-
sion numbers may be concatenated with semi colons,
for convenience without losing information. Multiple
protein sequences that are exactly the same can beeliminated by SQL with a simple automated function to
yield a distinct protein list of all implicated proteins that
differ by at least 1 amino in the protein sequence. Hence
the redundant versus distinct peptide and protein counts
of 10,138 distinct proteins with 3 peptides are conveni-
ent and easily reproducible metrics of the relative levels
of detection and the number of potential proteins using
commonly available software. Considered together, the
direct comparison of BLAST versus SQL indicate that
about 70% of the proteins detected in blood by three
peptides or more have no other close homologues in
circulation while an minority of proteins may have other
similar protein variants, isoforms or related sequences
in circulation.
Unique or characteristic peptide sequence analysis
Some fourteen thousand of the reported serum/plasma
proteins map to only one distinct protein sequence that
cannot be related to any other protein by BLAST but
these proteins can still be summarized at the peptide
and protein level using SQL. Moreover it is important to
Marshall et al. Clinical Proteomics 2014, 11:3 Page 16 of 21
http://www.clinicalproteomicsjournal.com/content/11/1/3remember that mass spectrometers most typically detect
peptides and not proteins. Thus a summary on the basis
of unique peptides that can be unambiguously analyzed
by LC-ESI-MS/MS is a meaningful metric for mass spec-
trometry experiments. If we accept the set of proteins
detected by at least one unique or characteristic peptide
not found in any other protein, as list of 12,130 proteins
are apparently in the blood and from these a conserva-
tive estimate of 3,858 proteins in the blood with reason-
able certainty was obtained.
Biological sources of error
It seems unlikely that cellular proteins observed with
three or more peptides, and in agreement between dif-
ferent research groups, could be identified erroneously.
However, it remains possible that at least some of these
proteins could be released from cells during blood col-
lection or processing. Some of the observed blood pro-
teins may have been released from the site of wounding
and diffused into the blood from the damaged skin tis-
sue or cells. The activation and degranulation of blood
cells is known to sometimes occur during the formation
of serum and might release the contents from cells that
burst during blood clotting. Red blood cells are anucle-
ate and so they might not seem like a rich source of nu-
clear factors. Similarly, platelets are anucleate and so at
least superficially [49] they are unlikely source of DNA
remodeling enzymes and transcription factors. Direct
measurements of secreted platelet proteins by LC-MS
make little mention of such cellular factors except for
well-known secreted proteins such as 14-3-3 proteins
and a single PI3K isoform and a few other similar pro-
teins [50,51]. It is known that neutrophils and potentially
other blood cells use expelled DNA as a net or snare to
entrap bacteria [52]. It remains possible that white blood
cell degranulation during processing results in expulsion
of nucleic acids and their binding proteins.
Analysis of the proteins released from leukocytes was
used to rule out the degranulation of white blood cells
during collection as the source of the transcription fac-
tors and other nuclear proteins in the blood. We tested
the hypothesis that the observed transcription factors,
receptors, signaling enzyme, DNA remodeling and other
signaling proteins observed in the FDBP were merely se-
creted by white blood cells during degranulation. To test
whether DNA binding factors and other cellular proteins
were released from white cells, human neutrophils were
isolated and degranulation was stimulated with the com-
bination of cytochalasen B and the bacterial peptide
fMLP. The results of the neutrophil stimulation experi-
ment showed that very few of the observed cellular
factors in blood were secreted from these abundant
white blood cells during degranualtion (not shown). The
abundance of cellular and nuclear materials in plasmasamples seems to indicate that a very efficient system
for releasing proteins from cells, such as secretion or
the release of exosomes, must be present to account
for such a large concentration of so many proteins
[7,8,35,53,54].Utility of the federated database of blood proteins
The FDBP will be useful only if the data are reliable and
easy to search or to manipulate. The above paragraphs
give the reasons for believing that highly reliable data
may be derived from the FDBP. To make the FDBP eas-
ily useful, we placed all of the data in a SQL database to
permit analysis of the data. The generic SQL and SAS
system can also be used to capture, organize and analyze
the results of bioinformatic algorithms such as BLAST
or the results of GO term analysis, as shown here. The
FDBP contains the BLAST and GO term data for the
proteins listed that can be rapidly and conveniently sum-
marized by a generic statistical analysis system such as R
or SAS [10]. The results of the many additional calcula-
tions are also made available in the provided excerpts of
SQL databases where the data may be analyzed and
graphically presented with SAS. The generic data sys-
tems SQL and SAS are sufficient to analyze proteomics
data and can derive the necessary attributes and distri-
butions of the data.
A further capacity to provide the calculated parent
and fragment m/z values for the peptides in the FDBP is
a significant advantage in designing experiments for un-
ambiguous identification and quantification by precise
mass spectrometric methods [10-12]. The mapping of
the peptides to the different protein sequences in the
FBPD will help to interpret proteomic results and for
the planning of experiments to make unambiguous pro-
tein determinations. Comparing the attributes between
the different related sequences or subsequences may be
informative and so collapsing the data into one repre-
sentative protein from each protein type may result in
the loss of valuable information. Where a feature of
interest is discovered in the data that span several simi-
lar, but distinct protein sequences, it is a simple task to
determine if the data available support the presence of
one or more related proteins, and which peptides are
unique to each protein, on a case by case basis in SQL
so long as all data is made available. A separate intensity
or frequency calculation can be made for each different
protein sequences regardless of homology to other
proteins [10-12,20,23,29]. Where such discrimination
between partial sequences, splice variants, predicted
proteins or allelic forms is made by subsequent experi-
ments, it will first be required to compare all of the pro-
tein sequences together in the same database to look for
sequences unique to specific proteins.
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The limit of quantification of an LC-ESI-MS/MS experi-
ment for a pure compound is typically about 100 femto
mol to 1 pico mol injected on column. Testing purified
protein digests on an LC-ESI-MS/MS running at 2 μl
per minute via an electropsray into an ion trap showed
10 f mol of standard proteins may be reproducibly and
confidently identified, 1 femto of peptide on column
seems to be at the detection limit and 100 atto mol of
digest on column was typically beyond the sensitivity of
a simple LC-ESI-MS/MS method for automatic identifi-
cation [19,55]. Based on the above estimates of system
sensitivity, we can calculate the range of required con-
centrations of the above mentioned regulatory proteins
in order for them to be detected in the approximate vol-
ume of serum/plasma used in the LC-MS experiments
summarized here. Since the plasma proteins were appar-
ently detectable by LC-ESI-MSMS then there must be at
least 1 to 10 femto mol of the serum/plasma peptide on
the column for identification by a simple ion trap. An-
derson and Anderson [56] estimated that the concentra-
tion of proteins that leak from tissue and diffuse from
cells could reach the nanogram per ml of blood. A pro-
tein with a mass of 50,000 Da present at 1 ng per ml has
a concentration of about 20 pico molar. Therefore, in
order to detect a protein in the 1 ng per ml range in
blood, a starting sample in the tens to hundreds of
microlitres of blood would have to be efficiently cap-
tured and fractionated, to deliver 1-10 femto mol in a
single discrete fraction within detection limits and in
agreement with the sample sizes used in some of the
studies cited here. These calculations are consistent with
previous observations of proteins known to be at least
as low as 1 ng/ml which have been observed by mass
spectrometry from a sample volume in the order of tens
to hundreds of microliters [19,55]. From these calcula-
tions, we infer proteins in the ng/ml or roughly pico
molar range are near the limit of robust detection by
electrospray with a simple ion trap in an unbiased LC-
MS experiment after a simple chromatographic pre-
fractionation of small samples [19] and this estimate has
been confirmed [43]. Protein biomarkers known to be in
the range of 1 ng/ml such as thyroglobulin and others
have been repeatedly detected by mass spectrometry
[19,55].
Cellular proteins in serum/plasma Tissue or cell leak-
age [56], secretion [11] or release of membrane-bound
exosomes [35] have been proposed as the pathways by
which cellular proteins, such as nucleic acid binding
proteins, might reach the plasma. It now appears that
there are significant amounts of intact nucleic acid
strings in plasma and that enough fetal DNA is released
into the blood stream of a pregnant mother to provide adraft fetal genome sequence [57]. The existence of nu-
cleic acid polymers in plasma probably leads to the pres-
ence of their binding proteins in circulation. Nucleic
acid binding proteins such as histones and high mobility
group proteins have previously been detected in serum/
plasma at concentrations as high as 1 to 40 ng/ml, using
Western blot and ELISA [58-62]. The cytokine receptors
or growth factor receptors that are known to exist in
serum/plasma in the ng per ml range were detected by
LC-MS. In contrast, there were no detections of cyto-
kines or growth factors, that exist at pico gram per ml
levels: From these observations, we conclude that the
concentrations of the proteins effectively detected in
serum/plasma by mass spectrometry closely match the
established detection limits of the LC-MS systems re-
ferred to in this review [10,11,19,42-44]. The presence of
many serum/plasma proteins, associated with circulation
or transport functions, proteolysis and metabolic pro-
cesses agrees with traditional views of the circulating
proteins [5,6]. However our meta analysis showed that
nuclear proteins with a role in DNA transcription and/
or RNA binding or metabolism as well as proteins asso-
ciated with signal transduction from the plasmalemma
receptor pathways were identified with impressive agree-
ment between different groups, confirming previous re-
ports [3,19,41,63,64].
Biomarker potential The collection of protein and pep-
tide information, along with the proteins’ cellular loca-
tions and molecular functions, together with expression
patterns in differentiated tissues and cells provides a
powerful means for elaborating hypotheses about poten-
tial biomarkers in serum/plasma, before validating them
by targeted assays. The detection of zinc finger and
other nucleic acid binding domains known to bind RNA
by mass spectrometry [3,19] correlates with the recent
discovery of circulating RNA in blood [35]. Purified exo-
somes from blood may also contain nucleic acids and
their binding proteins [35]. It may be possible to identify
and quantify the presumably non-coding RNA (ncRNA)
in the plasma that will help shed light on the function of
the RNA binding proteins detected in blood by mass
spectrometry. Complexes of nucleic acids and proteins,
including histones, are estimated to circulate at the level
of several hundreds of nanograms per ml [62]. It has
been suggested that modified histones, complexed with
nucleic acids in the plasma, may be biomarkers of cancer
[59,60]. High mobility group proteins and histones may
be secreted by cells in response to immunological activa-
tion and have been reported to be a biomarker of lupus
or other diseases reaching concentrations as high as
40 ng/ml in blood [58-60]. If relatively non-specific
DNA binding proteins such as HMG or histones may
serve as biomarkers, other more specific nucleic acid
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Figure 15 Note that exosomes may contain proteins like
ligands, receptors, transcription factors or RNA and potentially
DNA that may alter the target cells fate, differentiation
or functions.
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cance. However, for any plasma protein to serve as a re-
liable biomarker, it is important that the blood collection
and pre-anaytical procedures be standardized and docu-
mented [65].
Towards the definitive analysis of blood proteins
The reliability of the data presented here was previously
established using a variety of statistical methods includ-
ing distribution between NP versus XP protein libraries,
agreement between the data sets, peptide to protein dis-
tributions, and non-random distribution of the data over
specific GO term categories in agreement with expect-
ation values from goodness of fit tests of the MS/MS
spectra [20,23,29]. The peptide to protein distribution of
the database in toto is consistent with the veracity of the
correlation algorithms used by the different research
groups [23,29]. To date it seems that LC-ESI-MS/MS
of serum/plasma has revealed a total of 12,130 proteins
detected with at least 1 unique or characteristic pep-
tide not found in any other sequence and other these
3858 showed reasonable certainty. In contrast, 7,707
high confidence blood proteins were calculated by
BLAST. The related protein sequences can be analyzed
using SQL or BLAST, but this additional level of col-
lapse is not necessarily required to make comparisons of
detection frequency by Chi square or mean ion intensity
by ANOVA to detect proteins of potential interest. At
present, routine monitoring of proteins in blood requires
the use of monoclonal antibodies for standard ELISA
assays. However, there are not sufficient immunological
reagents to confirm the majority of the blood proteins
discovered to date by mass spectrometry. The limit of
detection of mass spectrometry may rival that of ELISA
after reproducible partition chromatography [19] and this
level of sensitivity has been confirmed [43]. Many blood
proteins discovered by mass spectrometry using sensitive
ion traps are near or below the present quantification
limits of ELISA or LC-ESI-MS/MS for routine analysis.
Extensive experimentation based on affinity reagents and/
or mass spectrometry will be required to establish the pro-
tein or peptide biomarkers of blood with the acceptable
standard of certainty provided by three independent bio-
physical or biochemical methods in agreement.
Conclusion
In conclusion, serum/plasma contains an abundance of
nuclear proteins including transcription factors, DNA
remodeling enzymes, RNA binding proteins, cellular
receptors and their associated proteins, or enzymes that
might serve as biomarkers of cell and tissue specific
diseases. These unexpected cellular factors indicate
that the blood hosts many cellular proteins, including
nucleic acid binding proteins and factors associated withintercellular signaling. The nucleic acid binding and sig-
naling factors in serum/plasma may still be functional.
The transport of secreted signal factors to distal cells
may have peri- or endocrine functions. The presence of
so much genomic DNA, RNA and their binding proteins
in circulation, presumably including mobile genetic ele-
ments [66], cannot preclude the transfer of transforma-
tive agents between cells (Figure 15). In conclusion, our
work confirms the reliable detection of transcription fac-
tors, chromatin remodeling factors, nucleic acid binding
proteins and receptor-mediated signaling enzymes in
blood fluid across different proteomic studies. It has
been suggested that cancerous cells or stem cells may se-
crete exosomes that contain receptors or other factors
such as RNA or transcription activators that if expressed
in target cells could permanently affect the recipient
cells’ fate or differentiation. A set of cellular regulatory
proteins that show great promise as biomarkers and
biotherapeutic proteins have been detected with high
confidence in human serum and plasma.Additional files
Additional file 1: The contents of the database queried for
transcription-associated proteins are shown without filtering.
The full list of factors may be found in Additional file 1. The figure was
produced using STRING evidence view. Colors: Green gene
neighborhood; red gene fusion; blue concurrence; black co-expression;
purple experiments; cyan databases; yellow text mining; and grey
homology.
Additional file 2: DNA remodeling factors in human blood.
The contents of the database were queried for DNA remodeling-
associated proteins and are shown without filtering. The full list of factors
may be found in Additional file 2. The figure was produced using STRING
evidence view. Colors: Green gene neighborhood; red gene fusion; blue
concurrence; black co-expression; purple experiments; cyan databases;
yellow text mining; and grey homology.
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http://www.clinicalproteomicsjournal.com/content/11/1/3Additional file 3: RNA binding and zinc finger proteins.
The contents of the database were queried for RNA binding or zinc
finger-associated proteins and are shown with filtering at n = 3. The full
list of factors may be found in Additional file 3. The figure was produced
using STRING evidence view. Colors: Green gene neighborhood; red gene
fusion; blue concurrence; black co-expression; purple experiments; cyan
databases; yellow text mining; and grey homology.
Additional file 4: The contents of the database were queried for
secretion-associated proteins and are shown without filtering.
The full list of protein may be found in Additional file 4. The figure was
produced using STRING evidence view. Colors: Green gene
neighborhood; red gene fusion; blue concurrence; black co-expression;
purple experiments; cyan databases; yellow text mining; and grey
homology.
Additional file 5: The receptor and signal transduction proteins in
human blood serum or plasma. The contents of the database wee
queried for receptors, kinases, phosphatase and cell signalling-associated
proteins and are shown with filtering at n = 5. The full list of factors may
be found in Additional file 5. The figure was produced using STRING
evidence view. Colors: Green gene neighborhood; red gene fusion; blue
concurrence; black co-expression; purple experiments; cyan databases;
yellow text mining; and grey homology.
Additional file 6: The cytokine, chemokine and interleukin proteins
of human blood plasma or serum. The contents of the database were
queried for cytokines, chemokines, interleukins and tumor necrosis factor
associated proteins and are shown without filtering. The full list of factors
may be found in Additional file 6. The figure was produced using STRING
evidence view. Colors: Green gene neighborhood; red gene fusion; blue
concurrence; black co-expression; purple experiments; cyan databases;
yellow text mining; and grey homology.
Additional file 7: The growth factor proteins of human blood
plasma or serum. The contents of the database were queried for
growth factor associated proteins and are shown without filtering. The
full list of factors may be found in Additional file 7. The figure was
produced using STRING evidence view. Colors: Green gene
neighborhood; red gene fusion; blue concurrence; black co-expression;
purple experiments; cyan databases; yellow text mining; and grey
homology.
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